Evidence map›Paper›PMID 37326395›Full record

ArticleActa medica academica2023

SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.

Fieke W Hoff, Suleyman Y Goksu, Naveen Premnath, Prapti A Patel, Ruth Ikpefan, Gurbakhash Kaur, Madhuri Vusirikala, Taha Bat, Weina Chen, Praveen Ramakrishnan Geethakumari and 7 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta medica academica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Fieke W HoffHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Suleyman Y GoksuHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Naveen PremnathHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Prapti A PatelHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Ruth IkpefanHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Gurbakhash KaurHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Madhuri VusirikalaHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Taha BatHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Weina ChenDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
Praveen Ramakrishnan GeethakumariHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Larry D AndersonHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Farrukh T AwanHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Robert H CollinsHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Olga K WeinbergDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
Alagarraju MuthukumarDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
Stephen S ChungHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Yazan F MadanatHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA. yazan.madanat@utsouthwestern.edu.
Harold C. Simmons Comprehensive Cancer CenterThe University of Texas Southwestern Medical Center · USSouthwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePatients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies.

methodsPatients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer.

resultsSixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine.

conclusionVaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.

Indexed as

COVID-19Hematologic NeoplasmsAntibody FormationCOVID-19 VaccinesHumansImmunoglobulin GSARS-CoV-2VaccinationCOVID-19 VaccinesImmunoglobulin GAntibody ResponseHematologic MalignancySARS-CoV-2 Vaccination

Identifiers

PMID37326395
PMCPMC10316070
OpenAlexW4380485826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.